364 related articles for article (PubMed ID: 9704468)
1. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
2. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
[TBL] [Abstract][Full Text] [Related]
4. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
5. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
6. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
7. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
8. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
9. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
12. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
13. Serious adverse events after HPA-incompatible platelet transfusions in an alloimmunized patient with leukaemia.
Sirén MK; Koponen A; Kekomäki R
Transfus Med; 1998 Sep; 8(3):221-4. PubMed ID: 9800295
[TBL] [Abstract][Full Text] [Related]
14. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
16. Alloimmunization to platelets in heavily transfused patients with sickle cell disease.
Friedman DF; Lukas MB; Jawad A; Larson PJ; Ohene-Frempong K; Manno CS
Blood; 1996 Oct; 88(8):3216-22. PubMed ID: 8874223
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
18. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
Brubaker DB; Romine M
Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
[TBL] [Abstract][Full Text] [Related]
19. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Pappalardo PA; Secord AR; Quitevis P; Haimowitz MD; Goldfinger D
Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
[TBL] [Abstract][Full Text] [Related]
20. Treatment of severe thrombocytopenia in alloimmunized, transfusion-refractory patients.
Ornstein DL; Mortara KL; Smith MB; Ririe DW; Shaughnessy PJ; Bickford DJ; Kissack BL
Mil Med; 2001 Mar; 166(3):269-74. PubMed ID: 11263033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
